The MPN AA is pleased to advise that the Jak inhibitor Fedratinib, (Inrebic) has been listed on the PBS, effective from 1 April 2026.
This means that a third Jak inhibitor is now available for haematologists to consider when selecting the most appropriate treatment for their myelofibrosis (MF) patients.
The product information brochure on Fedratinib (Inrebic) can be downloaded from the Therapeutic Goods Administration website. As that information brochure was specifically produced for myelofibrosis patients, the MPN AA has not developed our own separate treatment brochure. We have however available a patient brochure about What can I do to help myself – living well with an MPN.
The MPN AA provided a submission to the Pharmaceutical Benefits Advisory Committee in support of the listing of Fedratinib. To be able to access an additional treatment option for MF patients is invaluable.
